SAB Biotherapeutics (NASDAQ:SABS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $6.

BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...

H.C. Wainwright analyst Ed Arce affirms a Buy rating on shares of Inventiva (IVA) after the company announced the completion of patient ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Galectin Therapeutics (GALT – Research Report) today. The company’s shares closed ...

Surf Air Mobility Inc. (NYSE: SRFM) (the "Company"), a leading regional air mobility platform, closed on the previously announced purchase and sale of 2,000,000 shares of common stock (or pre-funded ...

Knightscope, Inc. (NASDAQ: KSCP), a leader in developing autonomous security robots and artificial intelligence technologies, closed on the previously announced sale of an aggregate of 625,000 shares ...

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.

Fintel reports that on March 31, 2025, HC Wainwright & Co. initiated coverage of Virax Biolabs Group (NasdaqCM:VRAX) with a ...

On Thursday, H.C. Wainwright reiterated a Neutral rating on Lyell Immunopharma (NASDAQ:LYEL) shares, with a steady price target of $1.00. The stock, currently trading at $0.67, has experienced ...